Table 6 Subgroup analysis of patients with ischemic and non-ischemic heart disease
Ischemic heart disease (n = 32) | Non-ischemic heart disease (n = 33) | P | |
|---|---|---|---|
Women | 6 (19) | 13 (39) | 0.07 |
Age (years) | 71 ± 8 | 63 ± 8 | < 0.001 |
BSA (m2) | 1.97 ± 0.19 | 2.03 ± 0.24 | 0.26 |
Diabetes | 4 (13) | 5 (15) | 1.0 |
QRS-duration (ms) | 167 ± 20 | 167 ± 13 | 0.96 |
LBBB | 26 (81) | 30 (91) | 0.30 |
Heart rate (beats/min) | 68 ± 15 | 67 ± 10 | 0.87 |
NIBP (mmHg) | |||
Systolic | 128 ± 18 | 127 ± 16 | 0.75 |
Diastolic | 75 ± 8 | 77 ± 9 | 0.47 |
Medication | |||
ACEI/ARB | 32 (100) | 33 (100) | 1.0 |
Betablocker | 28 (88) | 30 (91) | 0.66 |
Diuretics | 27 (84) | 29 (88) | 0.68 |
Antihyper-lipidemics | 29 (91) | 12 (36) | |
Platelet aggregation inhibitors | 24 (75) | 11 (33) | 0.001 |
NYHA Class | 0.32 | ||
NYHA Class II | 8 (25) | 12 (36) | |
NYHA Class III | 23 (72) | 18 (55) | |
NYHA Class IV | 1 (3) | 3 (9) | |
Echocardiagraphy | |||
ΔLVESV (%) | − 14 ± 20 | − 23 ± 24 | 0.12 |
CMR | |||
EDV (ml) | 323 ± 68 | 329 ± 148 | 0.82 |
ESV (ml) | 242 ± 61 | 250 ± 143 | 0.77 |
SV (ml) | 80 ± 26 | 79 ± 21 | 0.80 |
EF (%) | 25 ± 7 | 27 ± 9 | 0.40 |
CO (l/min) | 5.3 ± 1.6 | 5.3 ± 1.5 | 0.90 |
LVAVPD (mm) | 7.7 ± 3.0 | 8.9 ± 3.2 | 0.15 |
SVlong% | 49 ± 17 | 57 ± 19 | 0.10 |
SVlat% | 45 ± 18 | 37 ± 13 | 0.07 |
SVsept% | − 1 ± 14 | 2 ± 16 | 0.41 |
LGE positive | 28 (88%) | 12 (36%) | < 0.01 |